Target b2 with Hereditum Lc40 is a targeted probiotic designed to extend the benefits of breastfeeding and support overall infant immune health. This strain of Lactobacillus Fermentum (CECT5716) is clinically demonstrated to support breast health and resolve discomfort associated with mammary dysbiosis.

As many as one third of lactating women experience significant discomfort resulting in premature cessation of breastfeeding. Studies have shown that lactic acid bacteria isolated from human milk may prevent and resolve lactation-associated mammary dysbiosis. Colonizing Lactobacilli were isolated from the breast milk of healthy mothers. The strain was specifically selected for its safety of origin, antimicrobial, and immunomodulatory properties.

It is recommended to start supplementation with one capsule of Target b2 in the third trimester of pregnancy and continue while nursing to help prevent mammary dysbiosis. During an active case of mammary dysbiosis three capsules at 9 billion CFU is recommended.

Benefits and Features

• Clinically demonstrated to provide a safe and effective approach to preventing, reducing, and resolving lactation discomforts and dysbiosis^' 
• Designed to support overall infant immune health and extend the benefits of breastfeeding^' 
• Originally sourced from human mother's milk for superior safety and efficacy

This targeted probiotic supports breast health in nursing mothers. It is designed to extend the benefits of breastfeeding and support overall infant immune health.^' 

This is a statement of nutritional support. This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any diseases. Individual results may vary.